

Stephane Nancey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8180639/publications.pdf>

Version: 2024-02-01

110
papers

3,787
citations

117453

34
h-index

149479

56
g-index

118
all docs

118
docs citations

118
times ranked

4211
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of adherent and invasive <i>Escherichia coli</i> in Crohn's disease: lessons from the postoperative recurrence model. <i>Gut</i> , 2023, 72, 39-48.	6.1	22
2	Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 Study. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 579-588.	0.9	13
3	Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 787-797.e2.	2.4	11
4	Identification of Gene Expression Profiles Associated with an Increased Risk of Post-Operative Recurrence in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1269-1280.	0.6	15
5	Serum calprotectin is useful to confirm inflammatory bowel disease activity but not to predict relapse. <i>Clinical Immunology Communications</i> , 2022, 2, 33-38.	0.5	1
6	Impact of the Ileal Microbiota on Surgical Site Infections in Crohn's Disease: A Nationwide Prospective Cohort. <i>Journal of Crohn's and Colitis</i> , 2022, , .	0.6	3
7	Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study. <i>Digestive Diseases and Sciences</i> , 2022, , 1.	1.1	1
8	Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID. <i>Digestive and Liver Disease</i> , 2022, 54, 1350-1357.	0.4	0
9	The Kynurenine Pathway and Cancer: Why Keep It Simple When You Can Make It Complicated. <i>Cancers</i> , 2022, 14, 2793.	1.7	28
10	Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 1454-1462.	0.6	8
11	No Difference of Adalimumab Pharmacokinetics When Dosed at 40mg Every Week or 80mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose Intensification. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2744-2749.	1.1	6
12	A Practical Guide for Faecal Calprotectin Measurement: Myths and Realities. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 152-161.	0.6	31
13	Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus. <i>Digestive and Liver Disease</i> , 2021, 53, 35-43.	0.4	16
14	Effectiveness and Safety of Ustekinumab Intensification at 90 mg Every 4 Weeks in Crohn's Disease: A Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 222-227.	0.6	36
15	Low Levels of Fecal Calprotectin 3 Months After Surgery Predict Subsequent Endoscopic Postoperative Remission in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4429-4435.	1.1	8
16	Effect of COVID-19 pandemic on the workflow of endoscopy units: an international survey. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110066.	1.4	2
17	Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1289-1299.	1.9	30
18	Patients' real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group. <i>Digestive and Liver Disease</i> , 2021, 53, 434-441.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure” out of sight but not out of mind. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1319-1320.	1.9	0
20	Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. <i>United European Gastroenterology Journal</i> , 2021, 9, 552-560.	1.6	28
21	Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2914.	1.0	8
22	Letter: predicting treatment discontinuation in inflammatory bowel disease” anti-TNF trough levels and anti-drug antibodies. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 538-539.	1.9	1
23	Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 944-951.	1.9	24
24	Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels. <i>Inflammatory Bowel Diseases</i> , 2021, , .	0.9	5
25	Editorial: 5-ASA in IBD patients on biologics” stop or continue?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 843-844.	1.9	3
26	Selective Autophagy Receptors in Antiviral Defense. <i>Trends in Microbiology</i> , 2021, 29, 798-810.	3.5	21
27	The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 766-773.	0.6	11
28	Early detection of anti-drug antibodies during initiation of anti-tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1190-1200.	1.9	11
29	Faster and less invasive tools to identify patients with ileal colonization by adherent-invasive <i>E. coli</i> in Crohn's disease. <i>United European Gastroenterology Journal</i> , 2021, 9, 1007-1018.	1.6	11
30	Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 640-641.	1.9	1
31	Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 141-149.e2.	2.4	32
32	Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn's disease. <i>Gut</i> , 2020, 69, 462-472.	6.1	76
33	Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 620-627.e1.	2.4	21
34	Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1553-1560.e1.	2.4	35
35	Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 129-138.	1.9	87
36	Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID. <i>American Journal of Gastroenterology</i> , 2020, 115, 1812-1820.	0.2	50

#	ARTICLE	IF	CITATIONS
37	Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease. <i>Digestive and Liver Disease</i> , 2020, 52, 740-744.	0.4	12
38	Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2020, 115, 1084-1093.	0.2	40
39	Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 719-727.	1.9	39
40	Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial. <i>Gut</i> , 2020, 69, 1206-1212.	6.1	92
41	Toll-Interacting Protein Regulates Immune Cell Infiltration and Promotes Colitis-Associated Cancer. <i>IScience</i> , 2020, 23, 100891.	1.9	9
42	Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 896-903.	0.6	12
43	Surgery for Crohn's disease during pregnancy: A nationwide survey. <i>United European Gastroenterology Journal</i> , 2020, 8, 736-740.	1.6	7
44	Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1039-1046.	1.9	54
45	Infliximab induces clinical resolution of sacroiliitis that coincides with increased circulating FOXP3+ T cells in a patient with IPEX syndrome. <i>Joint Bone Spine</i> , 2020, 87, 483-486.	0.8	4
46	Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 40-53.	1.9	46
47	Usefulness of confocal laser endomicroscopy for predicting postoperative recurrence in patients with Crohn's disease: a pilot study. <i>Gastrointestinal Endoscopy</i> , 2019, 90, 151-157.	0.5	11
48	Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A GETAID Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1239-1247.	0.6	38
49	Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2610-2612.	2.4	34
50	T cell clonal expansions in ileal Crohn's disease are associated with smoking behaviour and postoperative recurrence. <i>Gut</i> , 2019, 68, 1961-1970.	6.1	35
51	Comparison of Immunoassays for Measuring Serum Levels of Golimumab and Antibodies Against Golimumab in Ulcerative Colitis: A Retrospective Observational Study. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 459-466.	1.0	12
52	Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease: A multicenter, retrospective, observational study. <i>Digestive and Liver Disease</i> , 2019, 51, 236-241.	0.4	14
53	Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 494-501.	2.4	62
54	Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy?. <i>Gut</i> , 2018, 67, gutjnl-2016-311892.	6.1	84

#	ARTICLE	IF	CITATIONS
55	IBD-INFO Questionnaire: A Multicenter French Up-to-Date Survey of Patient Knowledge in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 943-952.	0.9	14
56	High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 892-899.e2.	2.4	80
57	Is the Pharmacokinetic Profile of a First Anti-TNF Predictive of the Clinical Outcome and Pharmacokinetics of a Second Anti-TNF?. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2078-2085.	0.9	30
58	Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. <i>Gut</i> , 2018, 67, 53-60.	6.1	203
59	Prevalence of Yersinia Species in the Ileum of Crohn's Disease Patients and Controls. <i>Frontiers in Cellular and Infection Microbiology</i> , 2018, 8, 336.	1.8	17
60	Male gender, active smoking and previous intestinal resection are risk factors for postoperative endoscopic recurrence in Crohn's disease: results from a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 924-932.	1.9	71
61	Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 713-722.	1.9	10
62	Efficacy and Safety of Infliximab Tolerance Induction in Patients with Inflammatory Bowel Diseases who Experienced Acute Infusion Reactions. <i>Digestive Diseases</i> , 2018, 36, 417-426.	0.8	3
63	Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1089-1096.	0.6	15
64	Gut Inflammation in Mice Triggers Proliferation and Function of Mucosal Foxp3+Regulatory T Cells but Impairs Their Conversion from CD4+T Cells. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 105-117.	0.6	24
65	Risk of Rectal Neoplasia after Colectomy and Ileorectal Anastomosis for Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 930-935.	0.6	34
66	Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 2048-2053.	0.9	36
67	Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1425-1433.	0.9	149
68	Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 126-132.	0.9	26
69	Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis. <i>Digestive and Liver Disease</i> , 2017, 49, 11-16.	0.4	23
70	Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1750-1757.e3.	2.4	102
71	Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1294-1302.	0.6	62
72	Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1593-1601.e2.	2.4	168

#	ARTICLE	IF	CITATIONS
73	Isolated ileitis associated with primary sclerosing cholangitis in three patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 727-730.	0.6	1
74	Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1179-1185.	0.6	53
75	Costs of Crohn's Disease According to Severity States in France. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2924-2932.	0.9	6
76	Enrichment of Circulating and Mucosal Cytotoxic CD8 ⁺ T Cells Is Associated with Postoperative Endoscopic Recurrence in Patients with Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 338-345.	0.6	25
77	Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1362-1369.	0.9	24
78	Efficacy and Safety of Adalimumab 80 mg Weekly in Luminal Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1047-1053.	0.9	14
79	Levels of Fecal Calprotectin Are Associated With the Severity of Postoperative Endoscopic Recurrence in Asymptomatic Patients With Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2015, 110, 865-872.	0.2	114
80	Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic Strictures. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1770-1775.	2.4	84
81	Abdominal necrotic abscess from colonic fistula treated endoscopically. <i>Gastrointestinal Endoscopy</i> , 2015, 81, 1026-1027.	0.5	0
82	Long-term disease course in a patient with severe neonatal IPEX syndrome. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, e43-e47.	0.7	11
83	Accuracies of Serum and Fecal S100 Proteins (Calprotectin and Calgranulin C) to Predict the Response to TNF Antagonists in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 331-336.	0.9	67
84	Response to Dai et al.. <i>American Journal of Gastroenterology</i> , 2015, 110, 1242.	0.2	0
85	Endoscopic and histologic characteristics of serrated lesions. <i>World Journal of Gastroenterology</i> , 2015, 21, 2896.	1.4	14
86	Endoscopic treatment of severe duodenal polyposis as an alternative to surgery for patients with familial adenomatous polyposis. <i>Gastrointestinal Endoscopy</i> , 2014, 80, 817-825.	0.5	46
87	Tacrolimus induction followed by maintenance monotherapy is useful in selected patients with moderate-to-severe ulcerative colitis refractory to prior treatment. <i>Digestive and Liver Disease</i> , 2014, 46, 875-880.	0.4	21
88	Su1281 Serrated Polyps in Patients With Inflammatory Bowel Disease: Endoscopic Characteristics Different From Serrated Polyps in the General Population. <i>Gastroenterology</i> , 2014, 146, S-424.	0.6	2
89	Human Herpesvirus 8-Associated Colorectal Kaposi's Sarcoma Occurring in a Drug-induced Immunocompromised Patient with Refractory Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, E12-E15.	0.9	14
90	Neopterin Is a Novel Reliable Fecal Marker as Accurate as Calprotectin for Predicting Endoscopic Disease Activity in Patients with Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1043-1052.	0.9	89

#	ARTICLE	IF	CITATIONS
91	Therapy with anti-TNF α antibody enhances number and function of Foxp3 ⁺ regulatory T cells in inflammatory bowel diseases. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 160-170.	0.9	93
92	Blockade of LTB ₄ /BLT1 pathway improves CD8 ⁺ T-cell-mediated colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 279-288.	0.9	9
93	Identification of <i>Mycobacterium cosmeticum</i> sp. as a novel colitogenic infectious agent in a nonimmunocompromised patient. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E128-E130.	0.9	9
94	Laparoscopic total colectomy: Does the indication influence the outcome?. <i>World Journal of Gastrointestinal Surgery</i> , 2011, 3, 177.	0.8	10
95	Lewis and Sumner syndrome following infliximab treatment in Crohn's disease: A report of 2 cases. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1450-1453.	0.9	8
96	A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization. <i>American Journal of Gastroenterology</i> , 2010, 105, 2617-2625.	0.2	164
97	CD4 ⁺ T Cells and <i>Lactobacillus casei</i> Control Relapsing Colitis Mediated by CD8 ⁺ T Cells. <i>Journal of Immunology</i> , 2009, 183, 5477-5486.	0.4	22
98	Comment on a Retraction: Author Response. <i>American Journal of Gastroenterology</i> , 2009, 104, 1864-1865.	0.2	0
99	A Positive Breath Hydrogen Test Does Not Predict the Occurrence of a Spontaneous Bacterial Peritonitis in Cirrhotic Patients with Ascites. <i>Digestion</i> , 2009, 79, 252-258.	1.2	4
100	Transcutaneous Posterior Tibial Nerve Stimulation for Fecal Incontinence in Inflammatory Bowel Disease Patients: A Therapeutic Option?. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 402-405.	0.9	43
101	Oral Probiotic Control Skin Inflammation by Acting on Both Effector and Regulatory T Cells. <i>PLoS ONE</i> , 2009, 4, e4903.	1.1	105
102	Serum Interleukin-6, Soluble Interleukin-6 Receptor and Crohn's Disease Activity. <i>Digestive Diseases and Sciences</i> , 2008, 53, 242-247.	1.1	46
103	A 6-Thioguanine Nucleotide Threshold Level of 400 pmol/8 × 10 ⁸ Erythrocytes Predicts Azathioprine Refractoriness in Patients With Inflammatory Bowel Disease and Normal TPMT Activity. <i>American Journal of Gastroenterology</i> , 2008, 103, 3115-3122.	0.2	45
104	CD8 ⁺ Cytotoxic T Cells Induce Relapsing Colitis in Normal Mice. <i>Gastroenterology</i> , 2006, 131, 485-496.	0.6	93
105	Tumor Necrosis Factor α Reduces Butyrate Oxidation In Vitro in Human Colonic Mucosa: A Link from Inflammatory Process to Mucosal Damage?. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 559-566.	0.9	20
106	Infliximab Treatment Does Not Induce Organ-specific or Nonorgan-specific Autoantibodies Other than Antinuclear and Anti-Double-Stranded DNA Autoantibodies in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 986-991.	0.9	42
107	Is scintigraphic double-track appearance a sign of severe acute episodes of ulcerative colitis?. <i>Gastroenterologie Clinique Et Biologique</i> , 2004, 28, 221-225.	0.9	6
108	Effects of local corticosteroids on acute experimental urticaria. <i>European Journal of Dermatology</i> , 2004, 14, 323-6.	0.3	11

#	ARTICLE	IF	CITATIONS
109	Butyrate strongly inhibits in vitro stimulated release of cytokines in blood. Digestive Diseases and Sciences, 2002, 47, 921-928.	1.1	55
110	Effective use of argon plasma coagulation in the treatment of severe radiation proctitis. Diseases of the Colon and Rectum, 2001, 44, 1766-1771.	0.7	78